Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00021827 · ClinicalTrials.gov registry record · Phase 2
PTHrP and Osteoporosis
A Phase 2 study, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- Phase 2
- Development phase
NCT00021827: Completed Phase 2 study, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
NCT00021827 is a Phase 2 study that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00021827, a Phase 2 study, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
PTH-related protein, or ''PTHrP'', is a hormone which was discovered in 1987. As its name implies, it is closely related to another hormone discovered in the 1920's named parathyroid hormone or ''PTH''. PTH has been shown to be effective in treating osteoporosis in both animals and humans. PTHrP has been shown to be effective in treating osteoporosis in laboratory animals, and there are strong scientific reasons to think that it may be effective in humans as well. However, no human trials with PTHrP in the treatment of osteoporosis have been performed. The studies in this trial are focussed on determining whether PTHrP can indeed increase bone mass in postmenopausal women with osteoporosis, when administered daily by subcutaneous injection for three months.
Interventions
- DRUG Parathyroid hormone-related protein or ''PTHrP''
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-06 |
| Est. Completion | 2001-12 |
| Phase | Phase 2 |
What the finished NCT00021827 record still lists
NCT00021827 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Parathyroid hormone-related protein or ''PTHrP'' is the first listed.
NCT00021827 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00021827 about?
NCT00021827 is a clinical study titled "PTHrP and Osteoporosis". PTH-related protein, or ''PTHrP'', is a hormone which was discovered in 1987. As its name implies, it is closely related to another hormone discovered in the 1920's named parathyroid hormone or ''PTH''. PTH has been shown to be effective in treating osteoporosis in both animals and humans. PTHrP has...
What is the current status of trial NCT00021827?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-06. Estimated completion is 2001-12.
What interventions are being tested in trial NCT00021827?
The interventions under investigation include: Parathyroid hormone-related protein or ''PTHrP'' (DRUG).
Who is sponsoring clinical trial NCT00021827?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia